The BIA has published a new guide to the Patent Box, developed by members of the Finance and Tax Advisory Committee and to be officially launched at the BIA Committee Summit on 22 February. Here, FTI Consulting’s Richard Turner takes a look at the impact the Patent Box has had on the UK life sciences sector.
This week we are gearing up for our 2018 Committee Summit taking place on Thursday, kindly hosted by Simmons and Simmons. The event will see around 180 expert BIA members gather for all eight of the BIA’s advisory committees coming together. In addition, this year we are running a plenary session on the implications of the Nagoya protocol for our sector.
The BIA’s Charity of the Year for 2017 was Alzheimer’s Research UK, and we are proud to have supported them throughout the year. In this blog, we take a quick look back at some of the highlights of our partnership.
New software to deliver faster and more accurate diagnoses in genetic epilepsies is the ambition of a ground-breaking partnership between Congenica, a global provider of clinical genomics interpretation software, and FutureNeuro, the SFI Research Centre for Chronic and Rare Neurological Diseases, supported by Science Foundation Ireland.
• Horizon out-licenses proprietary cell line and Helitron transposon gene editing technologies, demonstrating Horizon’s ability to generate revenues from internally derived IP
• Horizon retains commercial rights over improvements to its technology platforms to develop new cell line technologies and gene delivery IP that can be licensed to customers for applications in biomanufacturing, diagnostic reference standards, and cell therapy
Thank you to all our members who joined our Brexit lead event last week. It was great to be able to share perspectives on what is a fast moving key issue. I was pleased that members confirmed that we should stay our course on the Brexit priorities agreed last year, which we will keep stressing to the UK government, and with our European partner associations to the EU-27.
Last week saw the launch event for the China Biotech Special Interest Group. We had an excellent turn out at the China-Britain Business Council offices in Victoria, with people coming to hear BIA members talk about their different experiences in China.
The Biomedical Catalyst (BMC), a unique partnership between Innovate UK and the MRC, was established in 2012 as part of a wider package of measures to support the life sciences sector.
By Dr Michael Kipping, Innovation Lead, Biomedical Catalyst, Innovate UK.
ReViral, a UK-based biotech company focused on developing novel compounds targeting respiratory syncytial virus (RSV), today announced successful results from its Phase IIa placebo-controlled challenge trial in healthy adult subjects infected intranasally with respiratory syncytial virus (RSV).
Last week we released our latest quarterly report ‘Influencing and shaping our sector, BIA update October 2017 – January 2018’. These quarterly updates give an overview of key policy developments and the BIA’s continued engagement with policymakers, regulatory authorities and wider stakeholders on behalf of the UK life sciences industry.